Chiome Bioscience Balance Sheet Health
Financial Health criteria checks 5/6
Chiome Bioscience has a total shareholder equity of ¥1.2B and total debt of ¥291.0M, which brings its debt-to-equity ratio to 25.1%. Its total assets and total liabilities are ¥1.8B and ¥593.7M respectively.
Key information
25.1%
Debt to equity ratio
JP¥291.00m
Debt
Interest coverage ratio | n/a |
Cash | JP¥1.33b |
Equity | JP¥1.16b |
Total liabilities | JP¥593.73m |
Total assets | JP¥1.75b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4583's short term assets (¥1.6B) exceed its short term liabilities (¥539.0M).
Long Term Liabilities: 4583's short term assets (¥1.6B) exceed its long term liabilities (¥54.7M).
Debt to Equity History and Analysis
Debt Level: 4583 has more cash than its total debt.
Reducing Debt: 4583's debt to equity ratio has increased from 0% to 25.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4583 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4583 has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 3.8% each year.